Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology (KURA) and Kyowa Kirin will present eight ziftomenib abstracts at ASH on December 12–15, 2026, in New Orleans. Four oral presentations and four posters will cover combinations and additional populations in acute myeloid leukemia (AML).
The first FLT3 inhibitor combination results include KOMET-007, testing ziftomenib with quizartinib and intensive chemotherapy in newly diagnosed NPM1/FLT3-ITD co-mutated AML, and KOMET-008, testing ziftomenib with gilteritinib in relapsed or refractory NPM1/FLT3 co-mutated AML. Longer-term frontline results with venetoclax and azacitidine will address response durability, survival and safety; the companies say these support the ongoing Phase 3 KOMET-017 study. Other presentations cover exploratory activity beyond NPM1-mutated and KMT2A-rearranged AML, initial pediatric combination results and preclinical findings.
Kura Oncology (Nasdaq: KURA) will report its third quarter 2026 financial results after market close on November 10, 2026.
Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. A live webcast and archived replay will be available in the Events and Presentations section of the Investors tab on the company’s website.
Kura Oncology (KURA) and Caspian Therapeutics outlined plans to advance KO-7246, an oral menin inhibitor, toward clinical evaluation in diabetes.
Kura launched Caspian in September 2026 with $50 million in financing led by BVF Partners. Kura contributed KO-7246 and related intellectual property and know-how, retaining approximately half ownership. Caspian expects the financing to support initial clinical proof of concept and advancement of a second candidate.
Studies showed increased insulin and insulin-producing cells in diabetic mice, with no observed hypoglycemia, or low blood sugar. In responding insulin-deficient rats, glucose control and elevated stimulated C-peptide, a marker of the body's insulin production, persisted one month after treatment stopped. Human tissue samples showed selective insulin-producing cell proliferation. Development work needed before a clinical trial application is underway; Caspian plans a Phase 1 study assessing safety and insulin production.
Kura Oncology (Nasdaq: KURA) and Caspian Therapeutics will host an investor webcast on October 13, 2026, at 4:30 p.m. ET.
Management will discuss Caspian’s formation and review KO-7246 data featured in an oral presentation at the 62nd European Association for the Study of Diabetes Annual Meeting. The live webcast and replay will be available in the Investors tab’s Events and Presentations section on Kura’s website.
Kura Oncology (KURA) granted stock options covering 128,250 common shares to new employees on October 1, 2026, as employment inducements.
The awards went to nine employees under the amended 2023 Inducement Option Plan and were approved under Nasdaq Listing Rule 5635(c)(4). The exercise price is $10.65 per share, matching the stock’s closing price on the grant date. Options vest over four years: 25% on the first anniversary of the applicable vesting commencement date, followed by monthly vesting of the balance over 36 months. Vesting requires continued service through each applicable vesting date.
Kura Oncology (KURA) and Caspian Therapeutics presented preclinical KO-7246 diabetes findings at the EASD meeting in Milan.
In a Type 1 diabetes rat model, KO-7246 normalized fasting glucose in a majority of animals. Among responders, pancreatic islets regenerated to 40-90% of healthy-control levels by Day 56. Normal glucose levels and increased C-peptide persisted for at least one month after treatment stopped. In a Type 2 diabetes mouse model, β-cell mass rose 3.4-fold, and combining KO-7246 with semaglutide enhanced activity. Human-islet experiments showed increased β-cell proliferation and improved insulin release in response to glucose. KO-7246 is in IND-enabling development; Caspian plans a Phase 1 evaluation.
Kura Oncology (KURA) has launched Caspian Therapeutics, a separately financed subsidiary focused on small‑molecule menin inhibitors for diabetes and cardiometabolic diseases, backed by a $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura and others.
Caspian is built around KO‑7246, a next‑generation, highly selective menin inhibitor optimized for chronic metabolic use, plus related IP contributed by Kura. The financing is expected to fund KO‑7246 through IND‑enabling development and initial clinical proof of concept in diabetes and to support a second development candidate. Kura will retain approximately half of Caspian on a fully diluted basis, hold board representation, and provide services under an intercompany agreement, while remaining focused on oncology. Preclinical KO‑7246 data, showing selective β‑cell expansion and improved glycemic control in multiple diabetes models, will be presented orally at the EASD 2026 meeting.
Kura Oncology (KURA) appointed Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. She joins the senior leadership team and will report to President, Chief Executive Officer and Chairman Troy Wilson.
Fulk has more than 20 years of financial and operating leadership experience in biopharmaceuticals and high‑growth public companies. Her background includes over 15 years at Eli Lilly in roles spanning commercial finance, R&D, investor relations, treasury and global operations. She later served as CFO of Talkspace and Soleno Therapeutics, and COO/CFO of 120Water.
At Lilly, she was CFO of the U.S. Bio‑Medicines business with P&L responsibility for a $2.5 billion neuroscience and immunology franchise and provided financial leadership for an annual oncology R&D portfolio of approximately $1 billion.
Kura Oncology (KURA) granted inducement stock options for 48,450 shares to four new employees on September 1, 2026, under its 2023 Inducement Option Plan. The awards were approved by the Board’s Compensation Committee as inducements to employment in line with Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price of $12.89 per share, equal to the closing price on the grant date, and vests over four years: 25% after one year, with the remaining shares vesting monthly over the following 36 months, subject to continued service. The options are governed by the 2023 Inducement Option Plan and individual option agreements. Kura develops precision oncology medicines, including FDA-approved KOMZIFTI (ziftomenib) for relapsed or refractory NPM1-mutated acute myeloid leukemia.
Kura Oncology (Nasdaq: KURA) announced that management will present at three healthcare investor conferences in September 2026: Wells Fargo Healthcare Conference on September 8 at 3:45 p.m. ET, Cantor Global Healthcare Conference on September 9 at 9:10 a.m. ET, and Morgan Stanley Global Healthcare Conference on September 16 at 7:45 a.m. ET. Live audio webcasts and replays will be available in the Investors section of Kura’s website.